UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
November 25, 2014
 Date of Report (Date of Earliest Event Reported)
IntelGenx Technologies Corp.
(Exact Name of Registrant as Specified in its Charter)

Delaware	000-31187	870638336	
(State or other jurisdiction of	(Commission File	(IRS Employer Identification	
incorporation)	Number)	No.)	

6425 Abrams, Ville St- Laurent, Quebec, Canada	H4S 1X9	
(Address of principal executive offices)	(Zip Code)	
Registrant's telephone number, including area code: (514) 331-7440
Check the appropriate box below if the Form 8K fining is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[   ] Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[   ] Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events - News Release
IntelGenx Announces Settlement of U.S. Patent Litigation Related to Forfivo XL®

 	Exhibit	Description	
 	99.1	Press Release	
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 	INTELGENX TECHNOLOGIES CORP.	

Dated: November 25, 2014	By:	/s/ Paul A. Simmons	
 	 	Paul A. Simmons	
 	 	Chief Financial Officer	

IntelGenx Announces Settlement of U.S. Patent
Litigation Related to Forfivo XL®
Saint Laurent, Quebec - November 25, 2014 - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL® 450 mg tablets.
The Company will hold a call to discuss details of the settlement on Wednesday, December 3, 2014 at 10:00 AM ET. A live broadcast of the call will be available through the Company's website at www.intelgenx.com. Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations".
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: IntelGenx Management Update Call
Webcast Registration: CLICK HERE
(https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&eventid=905880&sessionid=1&key=C288D0D2E4AD25CA07C823826206D902&sourcepage=register)
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.
Investor Contact:
COCKRELL GROUP
T: 877.889.1972
investorrelations@thecockrellgroup.com
cockrellgroup.com
 
Company Contact:
Paul A. Simmons
Chief Financial Officer
IntelGenx Technologies Corp.
T: +1 514-331-7440
F: +1 514-331-0436
www.intelgenx.com